Neurotoxicity characterized after infusion of CD19 CAR-T cells

October 12, 2017

(HealthDay)—Patients with severe neurotoxicity after infusion of CD19-targeted chimeric antigen receptor-modified T (CAR-T) cells have evidence of endothelial activation, according to a study published online Oct. 12 in Cancer Discovery.

Juliane Gust, M.D., Ph.D., from the University of Washington in Seattle, and colleagues characterized neurologic adverse events in 133 adults with refractory B-cell malignancies treated with lymphodepletion chemotherapy followed by infusion of CD19 CAR-T cells.

The researchers found that there were correlations for , high CD19+ cells in bone marrow, high CAR-T cell dose, cytokine release syndrome, and pre-existing neurologic comorbidities with elevated risk of neurologic adverse events. There was evidence of endothelial activation among patients with severe neurotoxicity, including disseminated intravascular coagulation, capillary leak, and elevated blood-brain barrier (BBB) permeability. The permeable BBB did not protect the cerebrospinal fluid from high concentrations of systemic cytokines, including interferonγ, which induced brain vascular pericyte stress and secretion of endothelium-activating cytokines. The brain of a patient with fatal neurotoxicity had endothelial activation and multifocal vascular disruption. In patients who subsequently developed grade ≥ 4 neurotoxicity, biomarkers of endothelial activation were higher before treatment.

"We show and increased BBB permeability in neurotoxicity and find that with evidence of endothelial activation before lymphodepletion may be at increased risk of ," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry, including Juno Therapeutics, which partially funded the study.

Explore further: Studies advance methods to avert toxicity that can accompany immunotherapy

More information: Abstract/Full Text (subscription or payment may be required)

Related Stories

Studies advance methods to avert toxicity that can accompany immunotherapy

October 12, 2017
Two new papers from researchers at Fred Hutchinson Cancer Research Center provide the most comprehensive data yet reported on side effects of the emerging cancer immunotherapy strategy known as CAR T-cell therapy.

Patient's immune status associated with outcome following third-generation CAR T-cell therapy

September 6, 2017
Treatment with third-generation CAR T–cell therapy led to a complete response in six of 15 patients with a CD19-positive B-cell malignancy and overall survival was associated with the patient's immune status, according ...

CAR T-cell therapy for leukemia leads to remissions in clinical trial

July 17, 2017
Researchers at Fred Hutchinson Cancer Research Center showed about 70 percent of patients with the most common adult leukemia had their tumors shrink or disappear following an experimental chimeric antigen receptor (CAR) ...

Ca2+, the intercellular signal in arterioles

July 4, 2017
Vasoconstriction must be balanced with vasodilation, particularly in the arterioles that supply tissues with blood. Endothelial cells protrude through holes in the internal elastic lamina in arterioles to make contact with ...

CD19-targeting CAR T-cell immunotherapy yields high responses in treatment-resistant CLL

December 3, 2016
In a small, early phase trial, a high percentage of patients who had exhausted most traditional treatments for chronic lymphocytic leukemia saw their tumors shrink or even disappear after an infusion of a highly targeted, ...

Study shows promising clinical activity

December 5, 2016
Immune cellular therapy is a promising new area of cancer treatment. Anti-cancer therapeutics, such as chimeric antigen receptor (CAR) modified T cells, can be engineered to target tumor-associated antigens to attack and ...

Recommended for you

Scientists discover a mechanism of drug resistance in breast and ovarian cancer

July 18, 2018
There is a highly sophisticated way to treat some breast and ovarian cancers—a class of drugs called PARP inhibitors, designed to exploit the very defects that make tumors with certain mutations especially deadly. Yet this ...

Link found between bitter-taste sensitivity and cancer risk

July 18, 2018
High bitter-taste sensitivity is associated with a significantly increased risk of cancer in older British women, according to researchers who conducted a unique study of 5,500 women whose diet, lifestyle and health has been ...

Research identifies new breast cancer therapeutic target

July 18, 2018
Research led by Suresh Alahari, Ph.D., Professor of Biochemistry and Molecular Biology at LSU Health New Orleans School of Medicine, has shown for the first time that a tiny piece of RNA deregulates energy metabolism, an ...

Cancer patients may experience delayed skin effects of anti-PD-1 therapy

July 18, 2018
Cancer patients receiving anti-PD-1 therapies who develop lesions, eczema, psoriasis, or other forms of auto-immune diseases affecting the skin may experience those adverse reactions on a delay—sometimes even after treatment ...

Early supper associated with lower risk of breast and prostate cancer

July 18, 2018
Having an early supper or leaving an interval of at least two hours before going to bed are both associated with a lower risk of breast and prostate cancer. Specifically, people who take their evening meal before 9 p.m. or ...

Magnetized wire could be used to detect cancer in people, scientists report

July 16, 2018
A magnetic wire used to snag scarce and hard-to-capture tumor cells could prove to be a swift and effective tactic for early cancer detection, according to a study by researchers at the Stanford University School of Medicine.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.